An uncommon cause of severe bleeding during phenprocoumon treatment;Seltene ursache einer schweren weichteileinblutung unter therapie mit phenprocoumon

Deutsche Medizinische Wochenschrift

Volumn 126, Issue 25-26, 2001, Pages 754-756

  Neuhaus, T ^a   Hertfelder, H J ^b   Hess, L ^b   Oldenburg, J ^b   Walger, P ^a   Vetter, H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CARBOXYLASE; COUMARIN DERIVATIVE; PHENPROCOUMON; VALINE; VITAMIN K GROUP; WARFARIN;

AGED; AMINO ACID SUBSTITUTION; ANTICOAGULATION; ARTICLE; BLEEDING; CASE REPORT; CLINICAL FEATURE; DRUG CONTRAINDICATION; ECHOCARDIOGRAPHY; GENE MUTATION; HUMAN; IMPLANTATION; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME;

EID: 0035933470     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-15099     Document Type: Article

References (9)

1. Ala-10 mutations in the factor IX propeptide and haemorrhage in a patient treated with warfarin
2. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism
3. Diagnostik und therapie erworbener faktoreninhibitoren
4. Increased sensitivity of factor IX to phenprocoumon as a cause of bleeding in a patient with antiphospholipid antibody associated thrombosis
5. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX
6. Missense mutations at ALA-10 in the factor IX propeptide: An insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy
7. Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy
8. Should patients starting anticoagulant therapy be screened for the missense mutations at Ala-10 in the factor IX porpeptide?
9. No indication for aPTT screening in patients on oral anticoagulant therapy